about
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial.Final results of a prospective trial of a PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarcinoma.Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patientsFOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumabAflibercept a new target therapy in cancer treatment: a review.Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer.Results of preoperative hepatic arterial infusion chemotherapy in patients undergoing liver resection for colorectal liver metastases.A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer.Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer.Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phaTopoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients.Feasibility of an adaptive strategy in preoperative radiochemotherapy for rectal cancer with image-guided tomotherapy: boosting the dose to the shrinking tumor.FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patientsImmunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal CancerEZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzleInfluence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases
P50
Q30855372-722B8596-5876-4A47-BEF6-71E0773F5E32Q33364008-67183D52-D88B-4962-8556-E73CF311F738Q33367266-9A74694C-1DEB-4B55-9F09-77251CDFA6EAQ34444495-45F7E101-D941-4875-94D6-C5DE3FD95657Q34452900-88321DD3-3E80-4605-8A1C-D54F1C7404EFQ34492429-78BA08D2-2F1B-418F-808F-39D62EBE80BDQ34825323-0000CC98-9B05-44E5-AA13-943220812743Q38557254-14082D79-5AD6-40B3-B9FC-F7FED192A675Q38919065-E21002C8-0E52-462E-81E8-3075793C4D49Q45895324-978828FB-61AC-4CAF-ADDF-E24CB5DE6D45Q46454840-8E182E12-876E-4020-8C84-65EE33A5047AQ48018929-472DA565-3A87-483A-893A-0A15D1634B73Q48714573-3B41F2BF-A8D2-4087-A0DC-07D6C605C3A2Q51541898-BAB750DE-523F-49AA-9B71-1F0DB6353313Q51802900-ADDDBBC7-03ED-42FB-9F1D-3976FE88F975Q53179257-BF251EAA-643E-4764-B724-88CCB280A508Q60169777-CE80562C-A2A4-4F81-9C22-E9854F4118BDQ60169780-1546D2F3-5199-4A83-9FD4-CCA53AC73CC6Q62976255-609D74F9-259A-487B-B930-81B8AF5C1C26Q79294743-A54B83B7-2E9A-48DA-BAE5-331A230C76E1
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Monica Ronzoni
@ast
Monica Ronzoni
@en
Monica Ronzoni
@es
Monica Ronzoni
@nl
Monica Ronzoni
@sl
type
label
Monica Ronzoni
@ast
Monica Ronzoni
@en
Monica Ronzoni
@es
Monica Ronzoni
@nl
Monica Ronzoni
@sl
prefLabel
Monica Ronzoni
@ast
Monica Ronzoni
@en
Monica Ronzoni
@es
Monica Ronzoni
@nl
Monica Ronzoni
@sl
P106
P1153
6603465542
P21
P31
P496
0000-0002-2845-275X